Belvedere Trading
CRNX icon

Belvedere Trading’s Crinetics Pharmaceuticals CRNX Stock Holding History

Belvedere Trading’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200
Closed -$9.36K – 737
2024
Q1 		$9.36K Buy
+200
New +$7.83K ﹤0.01% 606
2023
Q4 		– Sell
-9,400
Closed -$280K – 839
2023
Q3 		$280K Buy
+9,400
New +$194K ﹤0.01% 171

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Belvedere Trading's CRNX Position: Q2 2024 in Review

Belvedere Trading sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2024, closing a stake of 2,114 shares — an estimated $99K sold.

Belvedere Trading first reported a position in CRNX in Q3 2023 and held it in 2 quarters. The position peaked at $101K in Q3 2023. 234 funds tracked by Wall St. Rank hold CRNX as of Q2 2024.

  • Belvedere Trading reported no remaining Crinetics Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 2,114 Crinetics Pharmaceuticals shares in Q2 2024, an estimated $99K.
  • Belvedere Trading first reported a position in Crinetics Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Belvedere Trading's Crinetics Pharmaceuticals position peaked at $101K in Q3 2023.
  • 234 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.